



MEDESIS PHARMA APPEALS THE DECISION OF THE MONTPELLIER COMMERCIAL COURT IN THE LEGAL DISPUTE WITH BPI FRANCE

Montpellier, July 6, 2023 at 6:00pm – MEDESIS PHARMA, a pharmaceutical biotechnology company developing drug candidates based on its proprietary technology for the administration of active pharmaceutical ingredients in nanomicelles by the buccal route, Aonys®, announces that it has lodged an appeal against the ruling of the Montpellier Commercial Court in the dispute with BPI France, with a view to obtaining a reversal of the ruling.

For further information, see the June 8, 2023 press release on the www.medesispharma.com website, "Stock market" menu, "Press release" page.

About Medesis Pharma

To advance the treatment of serious diseases without effective treatments, Medesis Pharma creates drug candidates based on its proprietary Aonys® technology for the oral administration of active ingredients in nanodroplet form, enabling active ingredients to be effectively delivered to all cells, with passage through the blood–brain barrier (BBB).

This innovative approach is being applied to future drugs to treat major diseases that do not have effective treatments: Alzheimer's disease, Huntington's disease, and resistant cancers.

Medesis Pharma is also developing treatments dedicated to populations contaminated or irradiated after a civil or military nuclear accident.

French biopharmaceutical company based near Montpellier, Medesis Pharma is the author of 15 scientific publications, holds 12 patent families and 72 patents, the result of 20 years of research.

Medesis Pharma shares are listed on Euronext Growth Paris: FR001844464 - ALMDP

For more information:

www.medesispharma.com

MEDESIS PHARMA

Jean Claude Maurel

Tel: +33 4 67 03 03 96

contact@medesispharma.com

CALYPTUS

Marie Calleux

Tel : +33 1 53 65 68 66

medesispharma@calyptus.net